Manchester scientists have a developed a new method to monitor the effect of anti-cancer drugs on very rare leukaemia stem cells. The approach potentially allows doctors to screen patients and personalise their treatment.
Feb 27, 2015
0
34
Professor Simon Rule, Professor in Haematology at Plymouth University Peninsula Schools of Medicine and Dentistry and Consultant Haematologist at Plymouth Hospitals NHS Trust, has been awarded a significant grant by Cancer ...
Nov 26, 2014
0
0
The emergence of molecular diagnostic testing in lung cancer offers new hope for patients battling the number one cancer killer in the United States and abroad. Now, for the first time after a decade of biomarker testing ...
Apr 3, 2013
0
0
In a major international study led by researchers at The University of Texas MD Anderson Cancer Center, the targeted therapy ibrutinib continues to show remarkable promise for the treatment of relapsed or refractory mantle ...
Jun 19, 2013
0
0
Brepocitinib is an oral drug that inhibits certain enzymes involved in inflammation—called tyrosine kinase 2 and Janus kinase 1—and is being tested for the treatment of several immunological diseases. A phase IIb randomized ...
May 17, 2023
0
2
August 29, 2013) St. Jude Children's Research Hospital scientists have identified a protein that certain high-risk acute lymphoblastic leukemia (ALL) cells need to survive and have used that knowledge to fashion a more effective ...
Aug 29, 2013
0
0
Approximately 68 percent of U.S. adults are overweight or obese, according to the National Cancer Institute, which puts them at greater risk for developing cancer, cardiovascular disease, diabetes and a host of other chronic ...
Dec 5, 2012
0
0
(HealthDay)—In a case report published online June 29 in the Journal of Clinical Pharmacy and Therapeutics, nephrotic syndrome is diagnosed in a 32-year-old female with relapsed Hodgkin's lymphoma who was on everolimus ...
Jul 7, 2017
0
0
Updated results from a Phase Ib/II clinical trial indicates that a novel therapeutic agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other ...
Dec 9, 2012
0
0
Most lung cancers are of a type called non-small-cell lung carcinoma (NSCLC). This type of cancer is relatively insensitive to chemotherapy, so NSCLC therapies are usually based on drug treatment. Alectinib is a drug commonly ...
Jan 22, 2021
0
4
